Navigation Links
Dyadic Netherlands To Develop Baking Enzymes For EU-Funded Research Project

JUPITER, Fla. and WAGENINGEN, Netherlands, Sept. 5, 2012 /PRNewswire/ -- Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the industrial enzyme, bioenergy, bio-based chemical and biopharmaceutical industries, announced today that its research and development center in the Netherlands is a participant in the HealthBread Project, a new multidisciplinary research program that has been awarded approximately one million Euro from the European Community's Seventh Framework Programme (FP7).

The HealthBread Project is a two year research program whose objective is to develop whole grain and white breads with improved nutritional value, taste and product quality by applying scientific and technological knowledge to the production and marketing of commercially viable, healthier bread. Dyadic Netherlands will receive approximately 143,000 Euro to develop commercial enzymes for the HealthBread Project which is scheduled to begin in October 2012.

Wim van der Wilden, the General Manager of Dyadic Netherlands, stated, "In continuing to enhance Dyadic's technologies and products for food applications, we are excited to work with leading scientific, baking and food organizations to demonstrate the effectiveness of Dyadic's C1 enzyme technology in producing healthier and more nutritious bread products. The value of these types of research programs is that they allow Dyadic to use and further enhance our technologies for specific enzyme applications in collaboration with leading organizations which can potentially lead to new sales and licensing opportunities."

The Netherlands Organization for Applied Scientific Research (TNO) will serve as the coordinator of the HealthBread Project which, in addition to Dyadic Netherlands, consists of the following research organizations, bakeries and large ingredient suppliers:

  • The Netherlands Organization for Applied Scientific Research (TNO)
  • VTT Technical Research Centre of Finland
  • Open Fields S.r.l. (Italy)
  • RTD Services (Austria)
  • Kampffmeyer Food Innovation GmbH (Germany)
  • Backerei Ripken (Germany)
  • Backerei Welter (Germany)
  • Bakkerij Kamstra (The Netherlands)
  • Netherlands Bakery Centre (NBC)(The Netherlands)
  • Meester Bakker Uljee (The Netherlands)
  • Backerei und Konditorei Kasses (Austria)
  • Backerei Lasser (Austria)
  • Geovita F.I. S.r.l. (Italy)
  • Molini Tandoi S.P.A. (Italy)
  • Panificio Fuse S. & C. snc (Italy)
  • Panificio REGAZZONI P. di C .F. REGAZZONI SNC (Italy)

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and others proteins for the industrial enzyme, bioenergy, bio-based chemical and biopharmaceutical industries.

Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the proteins which these technologies help produce. Please visit Dyadic's website at

Dyadic Netherlands is a wholly owned subsidiary of Dyadic based in Wageningen, The Netherlands that conducts research and development activities for the benefit of Dyadic, its collaborators and customers. Please visit Dyadic Netherlands' website at

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.

SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International to Announce Second Quarter 2012 Financial Results and Host Conference Call on Monday, August 13, 2012
2. Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
3. Dyadic International To Release First Quarter 2012 Financial Results And Host Conference Call
4. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
5. Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes
6. Allergan Opens New Research and Development Center in Bridgewater, New Jersey
7. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
8. Carnegie Mellons Jeffrey Hollinger Leads Research Team Developing New Tools To Ease Pain of Combat Injuries
9. New model of muscular dystrophy provides insight into disease development
10. New wave of technologies possible after ground-breaking analysis tool developed
11. IBN develops superior fuel cell material
Post Your Comments:
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - Aeterna ... request of IIROC on behalf of the Toronto Stock ... news release there are no corporate developments that would ... --> --> About ... . --> Aeterna Zentaris is ...
(Date:11/24/2015)... ... ... This fall, global software solutions leader SAP and AdVenture Capital brought together ... their BIG ideas to improve health and wellness in their schools. , Now, the ... title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl 50, and ...
(Date:11/24/2015)... New York , November 24, 2015 ... to a recent market research report released by Transparency ... projected to expand at a CAGR of 17.5% during ... "Non-invasive Prenatal Testing Market - Global Industry Analysis, Size, ... estimates the global non-invasive prenatal testing market to reach ...
Breaking Biology Technology:
(Date:10/27/2015)... 27, 2015 In the present market scenario, ... for various industry verticals such as banking, healthcare, defense, ... growing demand for secure & simplified access control and ... as hacking of bank accounts, misuse of users, , ... as PC,s, laptops, and smartphones are expected to provide ...
(Date:10/26/2015)... LAS VEGAS , Oct. 26, 2015 ... an innovator in modern authentication and a founding member ... launch of its latest version of the Nok Nok™ ... to use standards-based authentication that supports existing and emerging ... Suite is ideal for organizations deploying customer-facing applications that ...
(Date:10/22/2015)... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics software ... September 30, 2015.  --> --> ... a decrease of 33% compared to $6.0 million in the same ... was $2.2 million, or $0.10 per diluted share, which compared to ... a year ago.  --> --> ...
Breaking Biology News(10 mins):